• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 6

Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer

Video

During this segment, the panelists explore issues faced by managed care during treatment coverage decisions in castration-resistant prostate cancer (CRPC).

Michael Kolodziej, MD, discusses the high costs of newly developed agents, their role in drug-sequencing plans, and the Affordable Care Act’s impact on treatment coverage in CRPC.

Jeffrey D. Dunn, PharmD, MBA, explains the need for improvements in the research that can help provide better data about a drug’s effectiveness, and can help professionals determine a product’s cost and availability for health coverage.

David Quinn, MD, agrees with Dr Dunn and suggests that a patient’s improvements in health and overall outcomes must be additive to the cost of therapy. Dr Quinn further explains that by studying the value of agents used to treat CRPC, a paradigm shift may provide results about the benefits of options given to treat patients over a sequence of time.


Related Videos
Amit Singal, MD, UT Southwestern Medical Center
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Rashon Lane, PhD, MA
Dr Sophia Humphreys
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Leslie Fish, PharmD.
Ronesh Sinha, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.